Study shows HPV Vaccine Ineffective
MEDIA RELEASE
19 October
2012
Study shows HPV Vaccine
Ineffective
Family First NZ says that new evidence
has demolished claims of safety and effectiveness of the HPV
Vaccine, and the government is wasting hundreds of millions
of dollars on a vaccine that is unproven.
A systematic review of pre- and post-licensure trials of the HPV vaccine by a Canadian team shows that its effectiveness is not only overstated through the use of selective reporting or “cherry picking” data, but also completely unproven.
The study by the Department of
Ophthalmology and Visual Sciences at the University of
British Columbia says[i]:
“The widespread optimism
regarding HPV vaccines long-term benefits appears to rest on
a number of unproven assumptions (or such which are at odd
with factual evidence) and significant misinterpretation of
available data. For example, the claim that HPV vaccination
will result in approximately 70% reduction of cervical
cancers is made despite the fact that the clinical trials
data have not demonstrated to date that the vaccines have
actually prevented a single case of cervical cancer (let
alone cervical cancer death), nor that the current overly
optimistic surrogate marker-based extrapolations are
justified. Likewise, the notion that HPV vaccines have an
impressive safety profile is only supported by highly flawed
design of safety trials and is contrary to accumulating
evidence from vaccine safety surveillance databases and case
reports which continue to link HPV vaccination to serious
adverse outcomes (including death and permanent
disabilities).”
They conclude that “further reduction of cervical cancers might be best achieved by optimizing cervical screening (which carries no such risks) and targeting other factors of the disease rather than by the reliance on vaccines with questionable efficacy and safety profiles.”
“At the moment, students are being proselytized with unbalanced information through their schools or government organisations, and parents are being bullied into an uninformed response,” says Bob McCoskrie, National Director of Family First NZ.
“Significantly, figures released in Australia last year show that the number of Australian women killed by cervical cancer has halved since the introduction, not of Gardasil, but of the national screening program a decade ago.”
A recent report in the New York Times pointed out the vaccines have been studied for a relatively short period — both were licensed in 2006 and have been studied in clinical trails for at most six and a half years. Researchers have not yet demonstrated how long the immunity will last, or whether eliminating some strains of cancer-causing virus will decrease the body’s natural immunity to other strains.
A Harvard study also concluded that it might make more economic sense to rely on Pap smear screening alone which has effectively reduced cervical cancer death rates to very low levels.
“By spending $177m on this vaccine, there is less money available for other health issues including drugs like herceptin and heart disease medication,” says Mr McCoskrie.
“It seems that
the government has been a victim of aggressive marketing
worldwide by the vaccine makers with many questions
regarding its effectiveness still unanswered – including
its duration of protection, potential side-effects, and its
cost effectiveness. Regular pap smears are still necessary
and have been proved to be most effective in the fight
against cervical cancer.”
ENDS